MCM
TVRD

MAI Capital Management’s Tvardi Therapeutics TVRD Stock Holding History

MAI Capital Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-14
Closed -$45 – 5001
2026
Q1 		$45 Buy
14
+4
+40% +$16 ﹤0.01% 4881
2025
Q4 		$43 Hold
10
– – ﹤0.01% 4253
2025
Q3 		$390 Hold
10
– – ﹤0.01% 3651
2025
Q2 		$234 Hold
10
– – ﹤0.01% 3852
2025
Q1 		$153 Hold
10
– – ﹤0.01% 3339
2024
Q4 		$184 Buy
+10
New +$109 ﹤0.01% 3388

Other funds holding TVRD

SPC
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AFG
American Financial Group Cincinnati, Ohio $284M AUM 12.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $15.3B AUM 40.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return

MAI Capital Management's TVRD Position: Q2 2026 in Review

MAI Capital Management sold out of Tvardi Therapeutics (TVRD) in Q2 2026, closing a stake of 14 shares — an estimated $45 sold.

MAI Capital Management first reported a position in TVRD in Q4 2024 and held it in 6 quarters. The position peaked at $390 in Q3 2025. 58 funds tracked by Wall St. Rank hold TVRD as of Q2 2026.

  • MAI Capital Management reported no remaining Tvardi Therapeutics position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 14 Tvardi Therapeutics shares in Q2 2026, an estimated $45.
  • MAI Capital Management first reported a position in Tvardi Therapeutics in Q4 2024 and held it in 6 quarters.
  • MAI Capital Management's Tvardi Therapeutics position peaked at $390 in Q3 2025.
  • 58 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.